



(51) International Patent Classification:

C07K 16/28 (2006.01) A61K 47/68 (2017.01)

(21) International Application Number:

PCT/US2019/034701

(22) International Filing Date:

30 May 2019 (30.05.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/678,061 30 May 2018 (30.05.2018) US

(71) Applicant: **ABBVIE STEMCENTRX LLC** [US/US]; 1 North Waukegan Road, North Chicago, California 60064 (US).


(72) Inventors: **LIU, David**; 495 Loma Vista Terrace, Pacifica, California 94044 (US). **GAVRILYUK, Julia**; 400 East Jamie Court, South San Francisco, California 94080 (US). **SCHAMMEL, Alexander**; 25 Glendale Street, Apt. 3, San Francisco, California 94114 (US).

(74) Agent: **WARREN, Scott A.** et al.; Dechert LLP, Three Bryant Park, 1095 Avenue of the Americas, New York, New York 10036-6797 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: ANTI-SEZ6 ANTIBODY DRUG CONJUGATES AND METHODS OF USE



(57) Abstract: Provided are novel anti-SEZ6 antibodies and antibody drug conjugates, and methods of using such anti-SEZ6 antibodies and antibody drug conjugates to treat cancer.

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*